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Abstract (150 words) 
Introduction 
Increasing imaging evidence supports the role of neuroinflammation in dementia pathogenesis. 
Despite this, the spatial association within the brain has not been comprehensively meta-analysed. 
Methods 
We searched literature databases for case-control studies examining the levels of translocator 
protein (TSPO) levels, representing neuroinflammation, in region of interest analyses between 
healthy controls and mild cognitive impairment (MCI) or Alzheimer’s disease (AD) subjects. 
Standardised mean difference effect sizes were calculated and results meta-analysed using random-
effects models. 
Results 
The literature search identified 28 studies for inclusion, covering 37 different brain regions of 
interest. Compared to healthy controls, AD subjects had widespread increased TSPO levels 
throughout the brain, with the largest effects seen in fronto-temporo-parieto-occipital regions. MCI 
subjects also had increased TSPO levels, mainly within the neocortex, however, the effects were 
more modest. 
Discussion 
Neuroinflammation effect sizes increases and disperses from MCI to AD, relative to healthy controls.  
 
Keywords (5 - 15) 
Mild cognitive impairment, Alzheimer’s disease, neuroinflammation, meta-analysis, translocator 
protein, positron emission tomography, neuroimaging 
1. Introduction 
Alongside the classical pathological hallmarks of Alzheimer’s disease (AD), such as misfolded and 
aggregated proteins, neuroinflammation is appreciated as a major driver in disease pathogenesis 
and progression [1,2]. Genetic variants in inflammatory-related genes, such as those central to 
microglial function, have been implicated in AD [3]. Further, there is a reduced risk of AD in those 
taking non-steroidal anti-inflammatory drugs (NSAIDS) long-term, albeit at the epidemiological level 
[4]. Therefore, understanding the neuroinflammatory involvement during dementia is of high 
interest for both disease monitoring and therapeutic interventions. 
Microglia and astrocytes are the predominant mediators of inflammation within the central nervous 
system, applicable to their ability to respond to neuropathologies [5,6], and have been prime 
candidates to investigate the neuroinflammatory process during disease pathogenesis. Over recent 
years, a great deal of attention has shifted to neuroimaging approaches which, unlike histological 
analyses, can elaborate on the morphological effects in living patients [7]. Specifically, positron 
emission tomography (PET) advances have been integral in quantifying levels of inflammation 
throughout the brain during dementia and have revealed neuroinflammation as one of the earliest 
detectable biomarkers in the disease [2,8]. 
The translocator protein-18 kDa (TSPO) is a transmembrane domain protein found on the outer 
mitochondrial membrane. It is widely distributed in various tissues, with minimal expression within 
the brain at physiological levels [9]. Upon microglial and astrocyte activation TSPO levels are 
significantly increased [10,11], supporting TSPO detection as an in vivo marker of 
neuroinflammation. Since the first use of TSPO ligands in PET on AD subjects by Groom and 
colleagues at the turn of the 21st century [12], numerous groups have added further reports through 
the use of various TSPO ligands (as reviewed in [7]). However, reports so far concern analyses on 
study-specific regions of interest, restricting the interpretation of morphological differences in 
neuroinflammation during MCI and AD. Further, due to the demanding nature of PET protocols, 
studies often contain relatively few (n < 10) subjects [12–17], thus limiting the power of analyses. 
In this regard, we performed the first meta-analyses concerning all brain regions reported in studies 
investigating TSPO levels in MCI and AD to provide a comprehensive analysis with increased 
statistical power. 
2. Methods 
2.1. Search strategy 
All meta-analyses were performed according to the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines [18]. PubMed and Scopus literature databases were 
searched, up to 31st July 2018, and were restricted to journal articles written in English. 
Search terms used to find potential articles were as follows: (“Positron-emission tomography” OR 
“PET”) AND (“TSPO” OR “Translocator Protein” OR “18 kDa” OR “Neuroinflammation” OR "PK11195" 
OR "microglia" OR "benzodiazepine") AND (“Alzheimer’s disease” OR “dementia” OR “cognitive 
impairment” OR “MCI” OR “Prodromal”). We also manually searched any included articles for 
additional relevant references. A standardised review protocol has not been published. 
2.2. Eligibility criteria 
Studies were included in the meta-analysis based on the following criteria: (1) written in English, (2) 
measured TSPO binding using PET; (3) participants were stratified into healthy control (HC) and MCI 
and/or AD groups; (4) performed a region of interest analysis; (5) TSPO levels were reported. 
We excluded studies if they: (1) were of an interventional study design; (2) contained a duplicate 
study population; (3) did not perform a region of interest analysis. 
2.3. Data extraction 
The following data was extracted from each included study: (1) the TSPO ligand used; (2) the 
outcome used to measure TSPO levels; (3) the number of subjects in each group; (4) the average age 
of subjects in each group; (5) the proportion of female subjects in each group; (6) the average MMSE 
scores of subjects in each group; (7) the average value and standard deviation (SD) for the outcome 
of TSPO activation in each group. 
Where studies reported separate results for both hemispheres [19,20], results were averaged across 
hemispheres. When studies reported results in graphical format [13,14,21,22], mean and SD values 
were estimated by using the measurement tool in Adobe Reader (v.2018.011.20058). One study [20] 
presented their data as mean with 95% CI in a graphical format, therefore the corresponding author 
was contacted to request the raw tabulated data, which they kindly provided. One study reported 
standard error (SE) [23], as opposed to SD, therefore values were converted to SD using the 
following formula: SD = SE x √N. Where multiple studies utilised the same study population, we 
selected the study containing the larger study population for inclusion and excluded the duplicate 
population. One study [24] reported combined results for the MCI and AD groups in a graphical 
format, therefore the corresponding author was contacted for separate results in mean and SD 
tabulated format, which they kindly provided. 
2.4. Quality assessment 
The quality of included studies was assessed using the Newcastle-Ottawa quality assessment scale 
for case-control studies [25]. A maximum score of 9 can be awarded, whereby studies with ≥ 7 
points are generally considered to be of high quality. The criteria for the assessment scale can be 
found in the supplementary material. 
2.5. Statistical analysis 
Meta-analysis was performed using the metafor package in R [26], when there were ≥2 studies for 
the same region of interest. Since TSPO levels were determined using different PET ligands and 
analytical methods, results were converted to standardised mean differences (SMD) between 
controls and MCI or AD groups. A positive result indicates higher TSPO levels in the cases (AD or 
MCI), compared to the healthy controls (HC). Results were meta-analysed using a random-effects 
model and are reported as SMD and 95% confidence intervals (CI). 
Statistical heterogeneity across studies was assessed using the I2 statistic. Subgroup analysis was 
performed to investigate the potential source of heterogeneity. Specifically, we anticipated the 
majority of variation to be explained by the type of TSPO ligand used, since second generation TSPO 
ligands offer superior neuroimaging characteristics, such as increased sensitivity and signal to noise 
ratios, compared to the initial generation [27]. We therefore stratified studies in two: 1st generation 
([11C]PK11195 or [11C](R)-PK11195) or 2nd generation ([11C]DAA1106, [11C]Vinpocetine, 
[11C]PBR28, [18F]FEDAA1106, [18F]DPA-714, [18F]FEPPA, [18F]FEMPA, [11C]DPA713) TSPO ligands. 
We also performed subgroup analysis based on study quality scores (<7 points / ≥ 7 points). 
Sensitivity analysis was conducted on those regions which reached statistical significance to assess 
the robustness of the result. Specifically, the leave-1-out method was applied which repeated the 
random effects model by leaving out one study at a time. The results of this analysis are reported as 
the number of studies which can be removed without affected the significance of the model.  
Mixed-effects meta-regressions were performed, through the rma function, when the number of 
studies permitted (≥ 10 studies) to determine the relationship between SMD and patient MMSE 
scores, a proxy of disease severity. 
Publication bias was tested when the number of studies permitted (> 2 studies), through the Egger 
regression test. Models which were significant after publication bias testing were further entered 
into trim-and-fill analysis. This method aims to identify and correct for funnel plot asymmetry by 
imputing possible missing studies. 
3. Results 
3.1. Study selection 
Following the literature searches, 528 articles were returned, of which 455 were excluded based on 
title and abstract suitability (Figure 1). After removal of duplicate results, the full text of 40 articles 
was examined. Following this, 13 articles were excluded because they did not meet our inclusion 
criteria, and 27 articles were eligible for inclusion in the meta-analyses.  
One article [28] reported results from two independent studies using different TSPO ligands, 
therefore these were treated as two separate studies. Overall, 28 studies were meta-analysed, of 
which 13 and 23 studies contained MCI and AD groups, respectively. 
3.2. Study characteristics 
The overall study characteristics of interest, including the type of PET ligand used, outcome, number 
of subjects, age of subjects, proportion of female subjects and subject MMSE scores for each 
included study is presented in Table 1. Quality scores of the included studies ranged between 4 - 9 
points (Supplementary Table 1), with the majority being of high quality ≥ 7 points. 
In total there were 37 regions of interest which were eligible for meta-analysis. There regions are 
defined as: amygdala, anterior cingulate (including: cortex and gyrus), caudate, cerebellum, cortex 
(including: averaged cerebral cortex, cortical and whole cortex), entorhinal, frontal (including: cortex 
and lobe), gray matter, hippocampus, inferior and middle temporal (including: gyri and cortex), 
insula, lateral temporal, lingual gyrus, medial temporal (including: region, cortex, lobe, pole), 
midbrain, middle frontal (including: cortex and gyrus), occipital (including: cortex, lobe and lateral 
region), orbitofrontal, pallidum, parahippocampal (including: cortex and gyrus), parietal (including: 
lobe, cortex, and lateral), inferior parietal (including: lobule and cortex), superior parietal (including: 
cortex and gyrus), posterior cingulate (including: gyrus and cortex), posterior temporal (including: 
lobe and cortex), precuneus, prefrontal cortex (including: dorsolateral and lateral), pons, putamen, 
sensorimotor cortex, striatum, superior frontal (including cortex and gyrus), superior temporal 
(including cortex and gyrus), temporal (including: cortex and lobe), thalamus, white matter 
(including: averaged cerebral white matter), whole brain. 
3.3. Meta-analysis between HC and AD subjects 
For the comparison between the HC and AD groups, 36 regions of interest were eligible for meta-
analysis, of which 27 regions had significantly higher TSPO levels in the AD subjects compared to the 
HC subjects (Figure 2, Table 2). The largest effects were seen in frontal, temporal, parietal and 
occipital regions, whilst the smallest effects were found in the thalamus, cerebellum and pons 
(Figure 2, Table 2). There were no differences in the putamen, cortex, lingual gyrus, caudate, insula, 
midbrain, sensorimotor cortex, white matter or gray matter. 
Sensitivity analysis through leave-1-out found the cerebellum, orbitofrontal cortex, pallidum, pons, 
striatum, entorhinal and lateral temporal region model effects were affected by one or more study 
exclusions (Supplementary Table 2). 
Publication bias was evident in the amygdala, anterior cingulate, posterior cingulate, middle frontal, 
prefrontal cortex, superior frontal, superior parietal, precuneus, entorhinal, inferior and middle 
temporal and parahippocampal regions (Supplementary Table 2). Apart from the amygdala model, 
imputing potential missing studies through trim-and-fill analysis failed to change these overall model 
effects (Supplementary Table 2). 
Significant study heterogeneity was detected in the majority of models (Table 2). To investigate 
potential sources of heterogeneity, subgrouping was performed for study quality (<7 / ≥ 7 quality 
score) and the type of TSPO ligand used (1st generation / 2nd generation). Heterogeneity in the 
anterior cingulate, caudate, superior frontal, parietal, putamen, hippocampus, inferior and middle 
temporal, lateral temporal and thalamus models were reduced when stratified by TSPO ligand type 
(Supplementary table 3). Further, when stratified by study quality, heterogeneity within the anterior 
cingulate, posterior cingulate, cerebellum, cortex, occipital, parietal, precuneus, putamen, 
hippocampus, inferior and middle temporal, parahippocampal and thalamus region models were 
reduced (Supplementary table 4). 
Meta-regression analysis was performed in models with ≥ 10 included studies to determine the 
association of AD subject MMSE scores with SMD effect sizes. There was no significant association in 
the anterior cingulate (estimate: -0.03; 95% CI: -0.19 - 0.13; P = 0.678), posterior cingulate (estimate: 
-0.10; 95% CI: -0.22 - 0.01; P = 0.086), cerebellum (estimate: -0.09; 95% CI: -0.21 - 0.04; P = 0.189), 
occipital (estimate: -0.11; 95% CI: -0.23 - 0.01; P = 0.082), thalamus (estimate: -0.03; 95% CI: -0.15 - 
0.09; P = 0.558) or hippocampus (estimate: -0.02; 95% CI: -0.18 - 0.13; P = 0.769) region models. 
However, there was a negative association between MMSE scores and SMD effect sizes in the 
parietal region model (estimate: -0.11, 95% CI: -0.21 - -0.02; P = 0.024, Figure 3). 
3.4. Meta-analysis between HC and MCI subjects 
There were 22 regions of interest meta-analysed for the comparisons between MCI and HC subjects 
(Figure 2, Table 3). From these, the MCI subjects had significantly more TSPO levels within the 
anterior cingulate, posterior cingulate, frontal, occipital, inferior parietal, precuneus, temporal, 
hippocampus, lateral temporal, medial temporal, thalamus and whole brain regions compared to HC 
subjects (Figure 2, Table 3). There were no differences in the amygdala, cerebellum, prefrontal 
cortex, superior parietal, sensorimotor cortex, striatum, entorhinal, inferior and middle temporal, 
parahippocampal and superior temporal regions between the groups (Figure 2, Table 3). 
Leave-1-out analysis was performed on the significant models and found that the anterior cingulate, 
lateral temporal and whole brain models were dependent on one or more studies included in the 
model (Supplementary Table 5). The posterior cingulate, frontal, occipital, parietal, precuneus, 
temporal, hippocampus, medial temporal and thalamus regions were unaffected by single study 
exclusions. 
Publication bias was only evident in the amygdala and striatum models (Supplementary Table 5). 
Despite this, trim-and-fill analysis failed to impute any missing studies (Supplementary Table 5). 
Significant study heterogeneity was only evident in the amygdala model (Table 3). However, this 
heterogeneity was not explained by the type of TSPO ligand used (Supplementary Table 6) or the 
quality of the included studies (Supplementary Table 7). 
Meta-regression was only performed on the posterior cingulate, which failed to report an 
association between patient MMSE scores and SMD values (estimate: -0.06; 95% CI: -0.26 - 0.14; P = 
0.536). 
4. Discussion 
The present meta-analysis contained 28 studies covering 37 different brain regions of interest for 
levels of neuroinflammation in AD and MCI, relative to controls. Levels of neuroinflammation were 
higher and more disperse in AD, whereas only modest levels were detected in MCI, primarily within 
the neocortex. Further, in studies concerning AD subjects, effect sizes were associated with disease 
severity (MMSE scores) in the parietal region. Collectively, these results are in agreement with 
recent reports of an increase in neuroinflammation with disease pathogenesis [2,29]. 
The latest hypothesis suggests levels of neuroinflammation peaks early on, possibly reflecting an 
initial anti-inflammatory response, following by a second peak during AD progression, which may 
indicate a pro-inflammatory shift [2,29,30]. This complex relationship may be due to the microglial 
reaction to the deposition and propagation of amyloid and hyperphosphorylated tau pathologies. 
Both amyloid and tau can be internalised by and activate microglia [5,6]. But, evidence suggests the 
spatio-temporal severity of each may decide upon the inflammatory state produced. For example, 
PET studies utilising TSPO and amyloid or tau ligands have shown strong inter-relationships of 
neuroinflammation with amyloid levels in early MCI [20,29–32], with little [32] or no correlations 
[31] with tau levels. This inflammatory peak during the prodromal phase may reflect the anti-
inflammatory response of microglia to amyloid. Amyloid deposition is initially seen throughout the 
neocortex, before expanding ventrally into the allocortex, midbrain, brainstem and eventually into 
cerebellar areas [33]. This pattern is in agreement with our results in the MCI subjects, where 
increased neuroinflammation was seen predominantly within regions associated with early amyloid 
deposition (e.g. frontal, occipital, parietal, temporal), whereas regions generally associated with 
later stages were less affected (e.g. striatum and cerebellum). On the other hand, 
neuroinflammation and tau associations are much closely aligned in AD, than they are in MCI [32]. 
Histological analyses also support this linear association of microgliosis with tau tangle burden 
during disease severity [34]. Again, our results corroborate the spatial propagation of tau during AD 
with all of the temporal regions affected by high effects of neuroinflammation, a region dominated 
with exacerbated tau aggregation during the disease course [35]. Collectively therefore, the spatial 
pattern of neuroinflammation during AD may be a reaction to initial amyloid deposition in the earlier 
phases, with a second hit during later tau spreading. 
A conceivable weakness of current PET studies targeting TSPO is that the ligands used can only 
indicate the activation level of that regions of interest, rather they are unable to differentiate 
between pro- and anti-inflammatory states of microglia and astrocytes. Future developments of 
ligands that can discriminate these inflammatory states, such as the promising recent insights into 
P2Y12R and P2X7R receptor targeting [36], will be vital in elucidating these associations with disease 
pathogenesis and further aid with potential therapy monitoring [37]. 
Another noteworthy finding from our analyses is the cerebellum as a region with significantly 
increased TSPO binding in the AD subjects. The cerebellum is often selected as a reference region 
during TSPO PET image analysis [12,21,30,38,39], mainly due to the belief that this region is 
relatively spared from AD pathology. Based on our findings, we would not recommend this structure 
as an appropriate reference region. For an alternative reference during image analysis, our results 
suggest the caudate (6 studies) or white matter (5 studies) may be a better alternative to the 
cerebellum. The lack of TSPO signal differences in the caudate, for example, is also corroborated in a 
an early report describing no difference in the number of microglia between control and AD caudate 
brain tissue [40]. 
Despite the strengths of the current investigation, it is important to address some important 
limitations. One challenge is that some of the regions of interest contained relatively few studies, 
especially involving MCI subjects, which can restrict the power of these analyses and limit 
publication bias analyses. Clearly, additional studies, particularly involving MCI subjects covering 
more regions of interest are warranted. Additionally, the included studies measured TSPO levels 
through a variety of analytical methods and different ligands. We did, however, anticipate such 
heterogeneity by applying random-effect models throughout and performing post-hoc subgroup 
analyses. 
Collectively, our findings are in agreement with the recent dual inflammatory hit hypothesis during 
AD progression. Further work concerning longitudinal PET analysis and additional ligand 
development is needed in the prodromal AD phases to fully understand the spatio-temporal 
sequence of neuroinflammatory events.  
Acknowledgements 
We would like to thank Dr’s Parbo and Passamonti for kindly agreeing to and providing the 
requested data to enable their study inclusion within the analysis. 
Funding 
This research did not receive any specific grant from funding agencies in the public, commercial, or 
not-for-profit sectors. 
Research in context (150 words) 
1. Systematic review: Using PubMed and Scopus databases, we reviewed the literature 
regarding levels of neuroinflammation, as measured by translocator protein binding during 
positron emission tomography, in mild cognitive impairment and Alzheimer’s disease. 
Despite recent systematic reviews on the topic, no meta-analysis has been performed. 
2. Interpretation: From an analysis involving 28 studies spanning a total of 37 brain regions of 
interest, we discovered increased and widespread neuroinflammation in Alzheimer’s 
disease, with less effects in those with mild cognitive impairment, when compared to 
healthy controls. 
3. Future directions: Future studies are needed for certain regions of interest containing low 
numbers of studies, especially involving mild cognitive impairment cases. Further, the 
development of inflammatory state specific ligands are warranted. Doing so will increase the 
statistical power of future meta-analyses and aid in identifying more regions impacted with 
neuroinflammation early in disease pathogenesis. 
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Figure 1. Flowchart illustrating the literature search strategy. 
Figure 2. Overall standardised mean difference for each region of interest model in the comparison 
between HC and AD subjects (left) and HC and MCI subjects (right). Detailed model reports are 
presented in Tables 2 and 3. 
Figure 3. Scatterplot demonstrating the association of AD MMSE score with standardised mean 
difference values in the parietal region. The size of study points is proportional to their precision. 
Lines presented are average predicted values with 95% confidence intervals (dashed lines).  
 
Table 1. Characteristics of included studies. 
   Subjects (n) Age (mean & SD) Female (%) MMSE (mean & SD) 
Study Ligand Outcome HC MCI AD HC MCI AD HC MCI AD HC MCI AD 
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† Median and inter-quartile range. 
‡ Removed from analysis because they contained the same subjects as in Edison et al., 2008. 
§ Removed from analysis because they contained the same subjects as in Yasuno et al., 2008. 
¶ Median and range. 
Table 2. Random effects meta-analyses results, stratified by region of interest, between HC and AD subjects. 
  Subjects  Overall effect Heterogeneity 
Region Number of studies HC AD SMD [95% CI] Z P I2 P 
Amygdala 5 [19,24,28,46] 71 53 1.17 [0.48 - 1.85] 3.34 0.001 65.5% 0.017 
Cingulate (Anterior) 13 [15,17,19,22,24,28,30,41–43,45,47] 146 148 0.81 [0.42 - 1.19] 4.14 <0.001 57.3% 0.006 
Cingulate (Posterior) 16 [14,15,17,19,22,24,28,30,41–43,45–48] 179 183 0.84 [0.51 - 1.17] 4.98 <0.001 53.4% 0.004 
Caudate 6 [15,16,24,28,48] 55 54 0.39 [-0.54 - 1.32] 0.82 0.413 81.1% 0.001 
Cerebellum 13 [13–16,19,22–24,28,38,42,48] 143 137 0.45 [0.06 - 0.83] 2.27 0.023 57.1% 0.006 
Cortex 3 [12,17,41] 25 29 0.61 [-0.74 - 1.96] 0.88 0.376 81.3% 0.006 
Frontal 9 [14–17,30,41,46–48] 92 108 0.57 [0.19 - 0.95] 2.96 0.003 37.1% 0.088 
Middle frontal 5 [22,24,28,43] 55 47 1.60 [1.08 - 2.12] 6.04 <0.001 23.0% 0.236 
Orbitofrontal cortex 2 [15,24] 20 18 0.76 [0.10 - 1.43] 2.24 0.025 0.0% 0.853 
Prefrontal cortex 6 [13,19,23,39,42,45] 80 72 0.94 [0.60 - 1.28] 5.38 <0.001 0.0% 0.416 
Superior frontal 4 [24,28,43] 45 37 1.31 [0.42 - 2.19] 2.90 0.004 68.6% 0.033 
Grey matter 2 [15,16] 13 18 0.02 [-0.70 - 0.74] 0.05 0.961 0.0% 0.396 
Insula 4 [15,16,19,24] 41 35 0.30 [-0.17 - 0.77] 1.26 0.209 0.0% 0.562 
Midbrain 2 [15,24] 20 18 0.24 [-1.07 - 1.55] 0.36 0.716 73.9% 0.050 
Occipital 17 [13,15–17,22–24,28,30,38,39,41,42,46–
48] 
205 208 0.82 [0.50 - 1.14] 5.06 <0.001 55.5% 0.003 
Lingual gyrus 2 [22,24] 23 19 0.55 [-0.57 - 1.67] 0.96 0.339 67.9% 0.078 
Pallidum 2 [19,24] 28 17 0.74 [0.09 - 1.39] 2.23 0.026 6.7% 0.301 
Parietal 15 [13–17,22,23,28,30,41,42,46–48] 161 169 0.77 [0.46 - 1.09] 4.81 <0.001 44.1% 0.028 
Inferior parietal 4 [19,24,38,39] 64 53 1.26 [0.75 - 1.76] 4.87 <0.001 32.5% 0.251 
Superior parietal 3 [22,24,39] 38 30 1.05 [0.39 - 1.70] 3.13 0.002 37.0% 0.202 
Precuneus 7 [24,28,30,38,39,43] 101 97 1.34 [0.72 - 1.97] 4.24 <0.001 72.8% 0.002 
Pons 4 [15,19,24,48] 42 36 0.49 [0.02 - 0.95] 2.06 0.039 0.0% 0.470 
Putamen 7 [15,16,19,24,28,48] 70 62 0.63 [-0.06 - 1.32] 1.79 0.074 70.7% 0.005 
Sensorimotor cortex 3 [12,14,45] 25 33 0.16 [-0.60 - 0.91] 0.41 0.684 46.0% 0.162 
Striatum 5 [13,17,41,42,45] 47 56 0.72 [0.10 - 1.35] 2.26 0.024 54.9% 0.068 
Temporal 7 [15–17,23,30,41,47] 80 91 0.92 [0.49 - 1.34] 4.18 <0.001 40.0% 0.107 
Entorhinal 3 [38,39,46] 57 55 1.07 [0.14 - 2.00] 2.25 0.024 80.3% 0.018 
Hippocampus 14 [15–17,19,23,24,28,30,38,39,43,46,47] 187 178 0.74 [0.35 - 1.13] 3.72 <0.001 66.6% 0.001 
Inferior and middle temporal 4 [19,24,38,39] 64 53 1.76 [0.97 - 2.56] 4.36 <0.001 67.2% 0.015 
Lateral temporal 6 [13,28,42,46,48] 66 62 0.95 [0.08 - 1.82] 2.13 0.033 79.8% 0.001 
Medial temporal 6 [13,14,17,24,42,48] 49 49 0.71 [0.29 - 1.12] 3.33 0.001 0.0% 0.401 
Parahippocampal 6 [19,24,28,38,43] 81 70 1.33 [0.67 - 1.99] 3.93 <0.001 68.2% 0.012 
Posterior temporal 2 [22,24] 23 19 1.41 [0.73 - 2.09] 4.04 <0.001 0.0% 0.464 
Superior temporal 5 [19,24,39,45,46] 77 66 0.83 [0.36 - 1.30] 3.46 0.001 42.6% 0.137 
Thalamus 17 [12,13,15–17,19,21–24,28,41,42,45,46,48] 186 182 0.43 [0.16 - 0.70] 3.07 0.002 37.7% 0.040 








Table 3. Random effects meta-analyses results, stratified by region of interest, between HC and MCI subjects 
  Subjects  Overall effect Heterogeneity 
Region Number of studies HC MCI SMD [95% CI] Z P I2 P 
Amygdala 3 [24,46,50] 43 30 0.90 [-0.41 - 2.21] 1.35 0.176 83.6% 0.001 
Cingulate (Anterior) 6 [8,24,30,44,45,47] 74 81 0.60 [0.13 - 1.08] 2.48 0.013 46.9% 0.095 
Cingulate (Posterior) 10 [8,14,20,24,30,44–47,50] 119 136 0.70 [0.42 - 0.98] 4.86 <0.001 10.6% 0.412 
Cerebellum 5 [14,24,38,44,50] 58 44 0.55 [-0.00 - 1.11] 1.95 0.051 42.2% 0.149 
Frontal 7 [8,14,20,30,46,47,50] 83 112 0.66 [0.36 - 0.97] 4.31 <0.001 0.0% 0.653 
Prefrontal cortex 3 [44,45,49] 37 28 0.40 [-0.17 - 0.97] 1.38 0.168 21.3% 0.270 
Occipital 8 [24,30,38,44,46,47,49,50] 116 103 0.58 [0.29 - 0.86] 3.94 <0.001 3.2% 0.471 
Parietal 8 [8,14,20,30,44,46,47,50] 93 119 0.75 [0.42 - 1.07] 4.53 <0.001 15.2% 0.285 
Inferior parietal 3 [24,38,49] 48 29 0.37 [-0.09 - 0.84] 1.56 0.118 0.0% 0.696 
Precuneus 4 [20,24,30,38] 64 78 0.90 [0.39 - 1.41] 3.47 <0.001 45.1% 0.142 
Sensorimotor cortex 2 [14,45] 18 16 0.00 [-0.68 - 0.68] -0.01 0.991 0.0% 0.459 
Striatum 3 [44,45,50] 32 30 0.48 [-0.37 - 1.32] 1.11 0.269 61.2% 0.082 
Temporal 5 [8,30,47,49,50] 61 81 0.87 [0.52 - 1.23] 4.87 <0.001 0.0% 0.443 
Entorhinal 2 [38,46] 42 21 0.24 [-0.28 - 0.77] 0.91 0.365 0.0% 0.548 
Hippocampus 7 [24,30,38,46,47,49,50] 106 96 0.46 [0.17 - 0.76] 3.12 0.002 0.0% 0.487 
Inferior and middle temporal 2 [24,38] 34 18 0.30 [-0.28 - 0.88] 1.02 0.309 0.0% 0.384 
Lateral temporal 3 [20,44,46] 41 43 0.74 [0.04 - 1.45] 2.06 0.040 52.3% 0.123 
Medial temporal 5 [14,20,24,44,50] 47 59 0.80 [0.38 - 1.22] 3.75 <0.001 0.0% 0.545 
Parahippocampal 2 [24,38] 34 18 0.45 [-0.17 - 1.08] 1.41 0.157 12.1% 0.286 
Superior temporal 3 [24,45,46] 47 27 0.18 [-0.31 - 0.66] 0.71 0.475 0.0% 0.318 
Thalamus 6 [21,24,44–46,50] 76 57 0.50 [0.14 - 0.86] 2.74 0.006 0.0% 0.550 
Whole brain 2 [8,50] 19 26 0.77 [0.15 -1.38] 2.44 0.015 0.0% 0.540 
 
 
 
 
